A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

1 hour ago 1

Seena Hassouna, The Motley Fool

Sun, March 15, 2026 astatine 2:59 PM CDT 4 min read

On February 17, 2026, Logos Global Management LP disclosed successful a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant (NASDAQ:IMVT), an estimated $24.53 cardinal commercialized based connected quarterly mean pricing.

Logos bought 1,100,000 further shares of Immunovant, a transaction estimated astatine $24.5 cardinal based connected mean quarterly closing prices.
The afloat presumption grew by astir $6.1 cardinal successful full worth implicit the quarter, reflecting some the caller shares and terms question successful the stock.
Logos finished the 4th holding 1,375,000 Immunovant shares, valued astatine astir $34.95 cardinal which represents 2.11% of the fund’s AUM, placing it extracurricular the fund’s apical 5 holdings

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Logos Global Management LP accrued its presumption successful Immunovant by 1,100,000 shares during the 4th fourth of 2025. The estimated transaction worth was $24.4 million, based connected the mean closing terms successful the quarter. The worth of the involvement astatine quarter-end roseate by $6.1 million, a fig that includes some trading and marketplace terms effects.

After the bargain Immunovant accounts for 2.11% of the fund’s 13F assets nether absorption (AUM)
Top holdings aft the filing:
- NASDAQ:RVMD: $238.50 cardinal (14.4% of AUM)
- NASDAQ:PRAX: $110.53 cardinal (6.7% of AUM)
- NASDAQ:IDYA: $108.03 cardinal (6.5% of AUM)
- NASDAQ:OLMA: $80.22 cardinal (4.9% of AUM)
- NASDAQ:CDTX: $68.48 cardinal (4.1% of AUM)
As of March 13 2026, shares of Immunovant were priced astatine $24.72, up 29.3% implicit the past twelvemonth and outperforming the S&P 500 by 10.58%.

Metric

Value

Price (as of marketplace adjacent 3/13/26)	$24.70
Market Capitalization	$5.03 billion
Net Income (TTM)	($464.20 million)
1-Year Price Change	29.24%

Immunovant is simply a subsidiary of Roivant Sciences (NASDAQ: ROIV) focused connected monoclonal antibody therapeutics for autoimmune diseases.What this transaction means for investors
Its pb candidate, batoclimab, has completed Phase III trials successful myasthenia gravis and is successful ongoing Phase III trials for thyroid oculus disease, with results expected successful the archetypal fractional of 2026.
The institution has nary approved products yet — gross depends wholly connected palmy objective and regulatory outcomes.

Immunovant is advancing batoclimab crossed aggregate autoimmune indications, with nary approved products yet and a regulatory way that hinges connected ongoing Phase III outcomes.

Logos Global Management is simply a San Francisco-based, healthcare-focused hedge money moving a concentrated, research-driven publication successful beingness sciences and biotech. This isn't a generalist money dipping into the assemblage — it's the benignant of steadfast that does heavy technological and regulatory diligence earlier sizing up a position.

Read Entire Article